Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,375 | 2 | 90.6% |
| Food and Beverage | $143.43 | 1 | 9.4% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $1,375 | 2 | $0 (2021) |
| Zimmer Biomet Holdings, Inc. | $143.43 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $1,375 | 2 | F. Hoffmann-La Roche AG ($1,375) |
| 2020 | $143.43 | 1 | Zimmer Biomet Holdings, Inc. ($143.43) |
All Payment Transactions
3 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/30/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $1,051.90 | Research |
| Study: A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC • Category: BioOncology | ||||||
| 06/30/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $322.60 | Research |
| Study: A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC • Category: BioOncology | ||||||
| 08/13/2020 | Zimmer Biomet Holdings, Inc. | Arcos (Device) | Food and Beverage | In-kind items and services | $143.43 | General |
| Category: Hips | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC | F. Hoffmann-La Roche AG | $1,375 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 1,876 | 4,300 | $832,280 | $148,818 |
| 2022 | 15 | 1,584 | 3,430 | $601,219 | $120,961 |
| 2021 | 19 | 1,944 | 3,759 | $664,161 | $139,494 |
| 2020 | 19 | 1,950 | 4,034 | $742,650 | $157,325 |
All Medicare Procedures & Services
68 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2023 | 421 | 1,269 | $332,478 | $38,687 | 11.6% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2023 | 245 | 1,209 | $124,321 | $28,342 | 22.8% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2023 | 146 | 307 | $120,958 | $21,081 | 17.4% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Facility | 2023 | 260 | 264 | $50,688 | $17,799 | 35.1% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2023 | 384 | 608 | $77,216 | $17,587 | 22.8% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2023 | 60 | 96 | $62,304 | $11,566 | 18.6% |
| 88360 | Microscopic genetic analysis of tumor, manual | Facility | 2023 | 88 | 157 | $23,803 | $5,469 | 23.0% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2023 | 98 | 152 | $14,638 | $3,341 | 22.8% |
| 88331 | Pathology examination of specimen during surgery, first tissue block | Facility | 2023 | 36 | 57 | $15,048 | $2,966 | 19.7% |
| 88363 | Examination of archival tissue for genetic analysis | Facility | 2023 | 27 | 27 | $1,669 | $441.18 | 26.4% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Facility | 2023 | 25 | 41 | $1,599 | $410.59 | 25.7% |
| 88334 | Pathology cytologic examination of specimen during surgery, each additional site | Facility | 2023 | 11 | 12 | $1,263 | $377.99 | 29.9% |
| 88304 | Pathology examination of tissue using a microscope, moderately low complexity | Facility | 2023 | 33 | 38 | $3,838 | $349.92 | 9.1% |
| 88311 | Preparation of tissue for examination by removing any calcium present | Facility | 2023 | 14 | 26 | $1,014 | $268.48 | 26.5% |
| 88300 | Pathology examination of tissue using a microscope, limited examination | Facility | 2023 | 28 | 37 | $1,443 | $132.16 | 9.2% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Facility | 2022 | 326 | 812 | $212,744 | $24,956 | 11.7% |
| 88341 | Special stained specimen slides to examine tissue, each additional procedure | Facility | 2022 | 213 | 1,031 | $66,685 | $24,309 | 36.5% |
| 88307 | Pathology examination of tissue using a microscope, moderately high complexity | Facility | 2022 | 116 | 261 | $102,834 | $18,076 | 17.6% |
| 88321 | Surgical pathology consultation and report on referred slides prepared elsewhere | Facility | 2022 | 202 | 208 | $39,936 | $14,415 | 36.1% |
| 88342 | Special stained specimen slides to examine tissue, initial procedure | Facility | 2022 | 307 | 449 | $57,023 | $13,111 | 23.0% |
| 88309 | Pathology examination of tissue using a microscope, high complexity | Facility | 2022 | 61 | 92 | $59,708 | $11,442 | 19.2% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Facility | 2022 | 92 | 189 | $14,553 | $4,214 | 29.0% |
| 88360 | Microscopic genetic analysis of tumor, manual | Facility | 2022 | 66 | 118 | $15,812 | $4,113 | 26.0% |
| 88331 | Pathology examination of specimen during surgery, first tissue block | Facility | 2022 | 40 | 72 | $19,008 | $3,793 | 20.0% |
| 88363 | Examination of archival tissue for genetic analysis | Facility | 2022 | 39 | 39 | $2,411 | $613.13 | 25.4% |
About Massimo D'apuzzo, MD PHD
Massimo D'apuzzo, MD PHD is a Anatomic Pathology healthcare provider based in Duarte, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/25/2007. The National Provider Identifier (NPI) number assigned to this provider is 1427104462.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Massimo D'apuzzo, MD PHD has received a total of $1,518 in payments from pharmaceutical and medical device companies, with $1,375 received in 2021. These payments were reported across 3 transactions from 2 companies. The most common payment nature is "" ($1,375).
As a Medicare-enrolled provider, D'apuzzo has provided services to 7,354 Medicare beneficiaries, totaling 15,523 services with total Medicare billing of $566,597. Data is available for 4 years (2020–2023), covering 68 distinct procedure/service records.
Practice Information
- Specialty Anatomic Pathology
- Other Specialties Neuropathology
- Location Duarte, CA
- Active Since 01/25/2007
- Last Updated 12/07/2020
- Taxonomy Code 207ZP0101X
- Entity Type Individual
- NPI Number 1427104462
Products in Payments
- TECENTRIQ (Biological) $1,375
- Arcos (Device) $143.43
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Anatomic Pathology Doctors in Duarte
Dr. Bharat Nathwani, Md, MD
Anatomic Pathology — Payments: $5,879
Dr. Sue Chang, Md, MD
Anatomic Pathology — Payments: $3,831
Dr. Mingjian You, M.d., Ph.d, M.D., PH.D
Anatomic Pathology — Payments: $32.69
Yu Liang, M.d., Ph.d, M.D., PH.D
Anatomic Pathology — Payments: $20.00
Mr. Huiqing Wu, Md, MD
Anatomic Pathology
Dr. Abul Ala Syed Rifat Mannan, Md, MD
Anatomic Pathology